Cargando…
Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor–positive advanced breast cancer
Despite advances in cytotoxic chemotherapy and targeted therapies, 5-year survival rates remain low for patients with advanced breast cancer at diagnosis. This highlights the limited effectiveness of current treatment options. An improved understanding of cellular functions associated with the devel...
Autor principal: | Beck, J Thaddeus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676614/ https://www.ncbi.nlm.nih.gov/pubmed/26675495 http://dx.doi.org/10.2147/OTT.S88037 |
Ejemplares similares
-
Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011) -
Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin
por: Khadir, Fatemeh, et al.
Publicado: (2018) -
New Developments in Mammalian Target of Rapamycin Inhibitors for the Treatment of Sarcoma
por: Agulnik, Mark
Publicado: (2012) -
Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2013) -
Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation
por: Leal, Rita, et al.
Publicado: (2017)